3,801 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by C M Bidwell & Associates Ltd.

C M Bidwell & Associates Ltd. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,801 shares of the biopharmaceutical company’s stock, valued at approximately $351,000.

A number of other large investors have also recently bought and sold shares of GILD. Southland Equity Partners LLC grew its stake in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 110 shares during the period. Berkshire Bank boosted its holdings in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 111 shares in the last quarter. CFO4Life Group LLC grew its position in shares of Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 112 shares during the period. Howe & Rusling Inc. increased its stake in shares of Gilead Sciences by 2.5% in the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 115 shares in the last quarter. Finally, GHP Investment Advisors Inc. lifted its position in shares of Gilead Sciences by 1.1% during the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 122 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on GILD shares. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Piper Sandler boosted their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, Morgan Stanley upped their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Stock Up 0.6 %

Shares of NASDAQ:GILD opened at $111.79 on Monday. The company has a market capitalization of $139.22 billion, a PE ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a fifty day moving average price of $105.48 and a two-hundred day moving average price of $95.00.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.